Breath test for early detection of pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to improve the early detection of pancreatic ductal adenocarcinoma (PDAC) by developing a non-invasive breath test that identifies volatile organic compounds (VOCs) associated with the disease. A total of 192 patients will provide samples for a pancreatic biobank, while an additional 771 patients will participate in the VAPOR 1 clinical study to validate the breath test. The study will analyze various biosamples, including breath, saliva, blood, and pancreatic tissue, to understand the mechanisms of VOC production in PDAC. The goal is to enable quicker diagnosis and treatment for patients with pancreatic cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Males and females
* Adult patients ≥ 18 years old
* VAPOR 1: patients with either a) Histologically confirmed PDAC\*; b) New-onset diabetes mellitus or chronic pancreatitis; or c) Non-specific gastrointestinal symptoms, but a radiologically-normal pancreas
* VAPOR Bioresource: patients undergoing pancreatic resection for a) Histologically confirmed PDAC\*; or b) Benign pancreatic disorders e.g. intraductal papillary mucinous neoplasms, pancreatic mucinous cystic neoplasms, chronic pancreatitis

Note: \*Patients undergoing surgery for suspected PDAC (without pre-operative histological confirmation) may be recruited assuming PDAC is confirmed within the resected specimen.

Exclusion Criteria:

* Patients who have already received chemotherapy, radiotherapy or surgery for their PDAC
* History of another cancer within the previous five years
* Previous upper gastrointestinal surgery
* Patients who are unable to provide a breath sample
* Pregnant women
* Patients unable to provide informed written consent
* VAPOR 1: Patients with active infection, receiving immunosuppressive medications or antibiotics within the preceding eight weeks
* VAPOR Bioresource: Patients receiving immunosuppressive medications within the preceding eight weeks

Where it's running

• Imperial College Healthcare NHS Trust
  London, United Kingdom Recruiting

Study contacts

• Principal investigator: Professor George B Hanna, PhD, FRCS — Imperial College London
• Study coordinator: Miss Caoimhe M Walsh, MBBS, MRCS
• Email: vapor@imperial.ac.uk
• Phone: +44 (0)20 7594 3653

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

• Daraxonrasib after surgery for resected pancreatic ductal adenocarcinoma (PDAC)

  This trial tests whether taking daraxonrasib after surgery can help prevent cancer from coming back in adults with resected PDAC who completed perioperative chemotherapy.

  Recruiting at 85 sites Phase 3 Revolution Medicines, Inc. · Birmingham, Alabama and 85 other locations · NCT07252232

• Breath test to detect pancreatic ductal adenocarcinoma (VAPOR2)

  This research will try a non-invasive breath test that looks for volatile organic compounds to see if it can detect pancreatic cancer in adults referred from primary care with possible pancreatic symptoms.

  Recruiting Imperial College London · London · NCT07243262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.